Navigation Links
BioLineRx Announces Promising Initial Phase 2 Results of Acute Myeloid Leukemia Treatment
Date:12/16/2013

ly effective in the mobilization of hematopoietic stem cells and white blood cells from the bone marrow to the peripheral blood.

BL-8040 also mobilizes cancer cells from the bone marrow and may therefore sensitize these cells to chemo therapy as well as 'targeted' anti-cancer therapy. Importantly, BL-8040 has also demonstrated a direct anti-cancer effect by inducing apoptosis (cell death). Pre-clinical studies show that BL-8040 is efficient, both alone and in combination with the anti-cancer drug Rituximab, in reducing bone marrow metastasis of lymphoma cells and stimulating lymphoma cell death. BL-8040 was licensed by BioLineRx from Biokine Therapeutics and was previously developed under the name BKT-140.

About Acute Myeloid Leukemia (AML)
Acute myeloid leukemia (AML) is a cancer of the blood and bone marrow and is the most common type of acute leukemia in adults. According to the American Cancer Society, approximately 14,500 new cases of AML will be diagnosed in the United States in 2013, with 66 being the median age of AML patients. The frontline treatment for patients with AML includes systemic combination induction chemotherapy. The median survival for patients receiving induction chemotherapy, which is associated with high mortality, is 6-12 months, with shorter survival for patients over the age of 60 or for those with certain gene or chromosome aberrations. The five-year survival rate for AML is 10-30 percent, due to relapsed or refractory disease associated with standard treatments.

About BioLineRx
BioLineRx is a publicly-traded, clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates. The Company in-licenses novel compounds primarily from academic institutions and biotech companies based in Israel, develops them through pre-clinical and/or clinical stages, and then partners with pharmaceutical companies fo
'/>"/>

SOURCE BioLineRx
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. BioLineRx Presents Positive Preclinical Results of Acute Myeloid Leukemia Treatment at ASH Conference
2. BioLineRx Announces New Positive Results in Phase 2a trial for Orally Available Inflammatory Bowel Disease Treatment
3. BioLineRx Reports Publication in Peer Review Journal of Positive Phase 1/2 Results in Stem Cell Mobilization for Multiple Myeloma
4. BioLineRx Reports Third Quarter 2013 Financial Results
5. BioLineRx to Report Third Quarter 2013 Results on November 13, 2013
6. BioLineRx to Hold Analyst and Investor Day in New York on November 21, 2013
7. BioLineRx Receives Regulatory Approval to Commence Phase 1/2 Trial for Novel Treatment of Celiac Disease
8. BioLineRx Announces In-Licensing of BL-9020, for Treatment of Type 1 Diabetes
9. BioLineRx Announces Regulatory Submission for Phase 1/2 Trial for Novel Treatment of Celiac Disease
10. BioLineRx Announces Receipt of a Notice of Allowance from USPTO for Patent on Use of BL-8020, an Oral, Interferon-Free Treatment for Hepatitis C
11. BioLineRx To Present At 15th Annual Rodman & Renshaw Global Investment Conference In New York
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... , Aug. 27, 2015  The Academy of ... and Drug Administration,s (FDA,s) draft guidance and proposed ... and biosimilars, to bear a nonproprietary name with ... been seeking a decision from the FDA on ... health care stakeholders urging the agency to use ...
(Date:8/27/2015)... WASHINGTON , Aug. 27, 2015 ... Collaborative (BPC) applauds the U.S. Food and Drug ... a distinguishable name in its draft guidance issued ... of biological products proposes distinguishable names, calling for ... includes an FDA-designated suffix. This proposal reflects the ...
(Date:8/27/2015)... -- Eli Lilly and Company (NYSE: LLY ) will ... September 17, 2015. Sue Mahony , Ph.D., senior ... Richard Gaynor , M.D., senior vice president of product ... in a fireside chat at 3:30 p.m., Eastern Daylight ... be available on the "Webcasts & Presentations" section of ...
Breaking Medicine Technology:AMCP Is Disappointed in FDA's Draft Guidance and Proposed Rule Calling for Suffix on Nonproprietary Names of Biological Products 2Biologics Prescribers Collaborative (BPC) Statement on FDA Draft Guidance entitled "Nonproprietary Naming of Biological Products" 2Lilly to Participate in Morgan Stanley Global Healthcare Conference 2
... Hedgeye Risk Management Healthcare team, led by Tom Tobin, will host ... Demographics of Demand and Profits in Healthcare," where we will be ... 1994-2002 was so good, and why the next decade looks so ... for hip, knee, and spine device growth. -   ...
... Oct. 6 Pharmaceutical and biotech companies reach much ... partnerships between R&D and marketing, balancing therapeutic innovation with ... requires companies to break down the walls that have ... strengths of both talented medical researchers and skillful marketers. ...
Cached Medicine Technology:Aging of America: Demographics of Demand and Profits in Healthcare 2Creating Partnerships Across R&D and Marketing to Ensure a Successful Global Launch 2
(Date:8/28/2015)... ... August 28, 2015 , ... The Kentucky State Department of ... for the position they are applying for, they are unable to pass the initial ... considering altering drug testing policies in order to be able to hire long-term, skilled ...
(Date:8/28/2015)... ... August 28, 2015 , ... For Dallas, the time is nearing for the ... USPI Tenet Health. , The American Heart Association hosts their well-known Heart Walk to ... that together, a difference can be made. Walkers can participate in the cause and ...
(Date:8/28/2015)... ... August 28, 2015 , ... The 6th Annual ... Brain Aneurysm Foundation has added yet another accolade to its cadre of widespread support—an ... , “With the help of the medical community and the University of Illinois ...
(Date:8/28/2015)... ... August 28, 2015 , ... Saint Petersburg, FL —Pocket Protein™, ... fat, carbs, sugar, gluten, lactose or caffeine in a convenient 2 oz. pouch ... CPG Editor’s Choice Awards. , Five consumer packaged goods (CPG) products were selected ...
(Date:8/28/2015)... , ... August 28, 2015 , ... ... nationwide. Addictions specialist, Dr. James Strawbridge, gives a new approach on solutions in ... should begin with the employer and employees getting together for meaningful group meetings. ...
Breaking Medicine News(10 mins):Health News:Hiring Obstacles: Drug Abuse a Problem for Workforce 2Health News:Hiring Obstacles: Drug Abuse a Problem for Workforce 3Health News:Hiring Obstacles: Drug Abuse a Problem for Workforce 4Health News:North Central Surgical Center’s Subsidiary Participates in Walk 2Health News:Chicago Mayor Pens Official Support of Annual Survivor in the City Event Benefitting Brain Aneurysm Foundation 2Health News:Chicago Mayor Pens Official Support of Annual Survivor in the City Event Benefitting Brain Aneurysm Foundation 3Health News:Pocket Protein™ Named 2015 CPG Editor’s Choice Award Finalist by Informa’s SupplySide 2Health News:Pocket Protein™ Named 2015 CPG Editor’s Choice Award Finalist by Informa’s SupplySide 3
... (EEG) test may hold the key to predicting ... drugs, particularly those related to psychiatric conditions. ... Clinical Neurophysiology , and now posted online, engineering ... machine learning to EEG patterns and successfully predicted ...
... ophthalmic pathologist at St. Michael,s Hospital, has won the prestigious ... of Medicine. Dr. Ycel received the $50,000 award for ... may lead to new treatments for glaucoma and eye tumours. ... has no lymphatics, the channels responsible for pumping fluid and ...
... you less upset about making errors, according to a ... journal of the Association for Psychological Science. The researchers ... while participants made mistakes on a test. Those who ... prominent response to mistakes than those who hadn,t. ...
... Arbor, Mich. A brief, motivational talk in the emergency ... peer violence or problems due to drinking, according to a ... Journal of the American Medical Association . ... work of University of Michigan Health System researchers who immersed ...
... a common blood disorder characterized by low hemoglobin levels, ... cancer. But researchers at Tel Aviv University have discovered ... hemoglobin levels can actually indicate a potential for colon ... Inbal Goldshtein, who works with Dr. Gabriel Chodick and ...
... Reporter , TUESDAY, Aug. 3 (HealthDay News) -- Foreign-born ... medical degrees abroad performed as well or better than ... analyzed records on nearly 250,000 patients hospitalized for a ... 2003-2006. The study included more than 6,100 doctors, including ...
Cached Medicine News:Health News:EEG predicts response to medication for schizophrenia 2Health News:EEG predicts response to medication for schizophrenia 3Health News:Brain study shows that thinking about God reduces distress -- but only for believers 2Health News:University of Michigan study: Pep talk to teens in the ER helped reduce violence, alcohol misuse 2Health News:University of Michigan study: Pep talk to teens in the ER helped reduce violence, alcohol misuse 3Health News:Is your hemoglobin 'trending'? 2Health News:Foreign-Trained Doctors As Good As U.S.-Trained Counterparts 2Health News:Foreign-Trained Doctors As Good As U.S.-Trained Counterparts 3
For the quantitative determination of Glucose in serum. Endpoint reaction (NAD -> NADH) measured at 340 nm. Linearity: 600 mg/dl. Liquid working reagent prepared with simple 1:9 dilution....
Amylase (EPS-G7, kinetics), Wavelength: 405 nm. Linear range; 5-1500 IU/L....
g-GT Liquid Reagent (Kinetic Method). Wavelength: 405 nm. Linear range: 0-200 U/mL. Prepare Working Reagent in the ratio of 5 parts R1 to 1 part of R2, (i.e., 50 mL R1 and 10 mL R2)....
Intended for the quantitative determination of calcium in serum. Endpoint Reaction. Reaction complete within one minute, color developed is stable for 30 minutes. Wavelength: 570 nm. Linearity: 16 mg...
Medicine Products: